At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year ...

Novartis's generics arm Sandoz is set to enrol patients with neovascular age-related macular degeneration (nAMD) in a late-stage trial of a biosimilar version of Bayer and Regeneron's Eylea ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period, reducing the number of injections by half ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Aflibercept, the generic name for Eylea, is indicated to improve eyesight in patients with nAMD and other specific neovascular retinal diseases. Biosimilars are essentially cut-rate generic ...